Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Jiangsu Egens Biotech Gains Rights to Hepatitis C Diagnostic from Israel's BATM

publication date: Jun 30, 2016
Jiangsu Egens Biotechnology has in-licensed China rights to a hepatitis C diagnostic test from BATM, an Israeli networking technology company with a diagnostic subsidiary, Adaltis. In 2014, Egens and Adaltis set up a China JV to import diagnostic products. The CFDA approved Adaltis' hepatitis C diagnostic in 2015, and the JV has contracted with Sinopharm to distribute the device in China. Egens says it combines biological material development, diagnostic reagent manufacturing and trade. More details....

Stock Symbol: (LSE: BVC)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital